With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism.
Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.
Over past few years, pharmaceutical companies have outsourced various aspects of their R&D and clinical research processes to specialty contract research service providers, in order to remain competitive, flexible, and profitable in the industry
Driven by the potential to confer sustained therapeutic effects and thereby, facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status
polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors
Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers.
Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market
Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery
Extensive research on cell encapsulation strategies has enabled the development of a variety of technologies capable of immobilizing / enclosing therapeutic entities within biocompatible matrices / carriers.
Results of compassionate and humane clinical study in patients with diabetic foot treated with agent developed with Cytoreg® therapeutic technology, successfully presented at the 81st Scientific Session of the American Diabetes Association 2021.
Global Sample Preparation Market Size, Share & Trends Analysis Report by Product Type (Instrument, Kits and Consumables), By Application (Proteomics, Genomics, Epigenomics, and Others), By End-User Forecast, 2020-2026
Using DNA to develop encoded libraries of pharmacological leads has enabled medical research community to assemble and maintain large collections of compounds in singular reaction tubes, capturing the attention of small and big pharma players
The approval of KYMRIAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity.
Rise in prevalence of chronic diseases and the corresponding need to medicate frequently, have led to an increase in demand for safe, self-administrable dosing options. Autoinjectors are considered among the leading product classes in this category
In order to reduce risk of device recalls and expedite time to market, medical device developers rely on contract service providers for regulatory submissions and navigating various challenging aspects of the product review and approval process
With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone
In addition, growing geriatric population in the U.S. is the major factor for growing cancer incidence across the U.S. For instance, 87% of all the cancers in the U.S. are diagnosed in people 50 years of age and older.
Increase in demand for noninvasive neurological biomarkers is expected to supplement the market growth. Furthermore, rise in number of research activities focused towards developing efficient biomarkers.
The global label free detection market is driven by rapid growth in pharmaceutical and biotechnology market, increasing adoption of innovative approaches in drug discovery, and rising initiatives & funding for various R&D activities.
Mobiloitte, a premier, full-service provider for Mobile and Web Application development has now added Biotechnology and Bio-informatics as part of its ever-increasing services and software solutions’ portfolio.